• Socio-Economic Access Matters
• Not a One Size Fits All: Personalized Medicine for the Underserved
• Policy Change to End Disparities

Special Session: COVID19 and Breast Cancer

Clinical Research Workshop

Research technology for clinicians (CTCs, cfDNA, Crispr)
Nicholas Turner, PhD, FRCP, BM, MA

Capturing patient reported outcomes
Oluwadamilola Fayanju, MD, MA, MPHS, FACS

Improving clinical trial design
Thomas Braun, PhD

Increasing clinical trial accrual
Deborah Collyar

FDA and Breast Cancer Workshop

Trastuzumab Deruxtecan
Preeti Narayan, MD
US Food and Drug Administration
Silver Spring, MD

Tucatinib
Mirat Shah, MD
US Food and Drug Administration
Silver Spring, MD

Sacituzumab
Christy Osgood, MD
US Food and Drug Administration
Silver Spring, MD

Global Breast Cancer Screening

Breast cancer screening trials in low and middle income countries: Lessons learned
Rengaswamy Sankaranarayanan, MD, MBBS

Weighing the benefits and harms of breast cancer screening
Philippe Autier, MD, MPH, PhD

EDUCATIONAL SESSIONS

Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

Special Topics in ER+ Breast Cancer

Special topics in early stage ER breast cancer
David Cameron, MBBS, MD

Special topics in metastatic ER+ breast cancer
Ingrid Mayer, MD, MSc

Special topics in ER+ breast cancer: mechanisms of therapeutic resistance
Robert Clarke, PhD

"Choosing Wisely" to Reduce the Toxicity and Burden of Radiation Therapy

Omitting radiotherapy in select situations
Reshma Jagsi, MD, DPhil

Hypofractionated radiotherapy and emerging RT approaches
Jean L. Wright, MD

Strategies to reduce cardiac toxicity
Rachel B. Jimenez, MD

Metastasis - A Moving Target

Evolution and heterogeneity
Andrea Bild, PhD

EMT 
Jing Yang, PhD

Dormancy
Lewis Chodosh, MD, PhD

1:00 pm - 3:00 pm

Triple Negative Breast Cancer

Deconstructing TNBC
Rebecca Dent, MD, MSc

State of the art treatment for neoadjuvant/adjuvant triple negative breast cancer
Lisa A. Carey, MD

Metastatic TNBC – What’s new on the horizon?
Jennifer K. Litton, MD

How and when to use immunotherapy and related toxicities
Javier Cortes, MD, PhD

SABCS with the Society of Surgical Oncology present De-escalation of Surgical Therapy: What Does the Data Support

DCIS
Pro 
E. Shelley Hwang, MD, MPH

Con
Sarah McLaughlin, MD

Exceptional responders to neoadjuvant chemotherapy
Pro
Joerg Heil, MD, PhD

Con
Monica Morrow, MD

DNA Damage Repair

Rescue DNA repair pathway and tumor immunity
Manjeet K. Rao, PhD

DNA repair defect as a driver of therapy resistance
Serena Nik-Zainal, MD, PhD

Targeting DDR
Simon Boulton, PhD

3:00 pm - 5:00 pm

Personalized HER2 Targeted Therapy 2020 - Are We There?

HER2 targeted therapy: Determinates of response and mechanisms of resistance
Rachel Schiff, PhD

Personalized treatment for early stage HER2-positive breast cancer
Aleix Prat, MD, PhD

Treatment of HER2-positive metastatic breast cancer - advances and challenges
Nancy U. Lin, MD

The Disparity Crisis in Breast Cancer

Tumor biology by race and ethnicity
John D. Carpten, PhD

Population based trends
Julie R. Palmer, ScD

Treatment differences and consequences
Mariana Chavez MacGregor, MD, MSC

Genomic and Epigenomic Alterations in Resistance 

Chromosomal instability and tumor immunity
Mathieu Lupien, PhD

The unique epigenetic state of invasive lobular breast cancers
Rinath Jeselsohn, MD

Targeting adaptive resistance
Gordon Mills, MD, PhD

5:00 pm - 7:00 pm

New Frontiers in Immunotherapy

Novel biomarkers in immune therapy response
Lajos Pusztai, MD, DPhil

New targets in myeloid cells
Xiang Zhang, PhD

Rationale for combination therapies (including pre-clinical data)
Sherene Loi, MBBS, FRACP, PhD

Accelerating Recovery After Breast Cancer

Toxicities of breast cancer treatment
Nora Lynn Henry, MD, PhD

Body image and sexual health
Ann H. Partridge, MD MPH

Oncofertility
Kathryn Ruddy, MD MPH

Tumor Inflammation (and Metastasis) 

Double edged swords in cancer progression and treatment – Lessons learned from investigating IL-1 and IFN signaling
Sandra S. McAllister, PhD

New insights to cancer-associated systemic inflammation
Karin de Visser, PhD

Obesity, inflammation and breast cancer - what's new
Pamela Goodwin, MD, FRCPC, MSc

WELCOME AND OVERVIEW

CAREER DEVELOPMENT FORUM

WELCOME AND OVERVIEW

Spotlight Session 5: Current Concepts and Controversies in Ductal Carcinoma in Situ (DCIS)

WELCOME AND OVERVIEW

DEBATE - All Breast Cancer Patients Should Have Germline Genetic Testing

Spotlight Session 10: Hereditary Predisposition

SPECIAL SESSION